Plain-English translation of NCT06196788 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating advanced pancreatic cancer using and nab-paclitaxel. Instead of delivering all the medication through your veins, this treatment uses a special catheter (a thin tube) to deliver the drugs directly into the blood vessels that feed the cancer tumor. The goal is to get stronger doses of medication to the cancer while reducing side effects.
Standard chemotherapy for advanced pancreatic cancer can cause difficult side effects like numbness, fatigue, nausea, and anemia that make it hard for patients to tolerate. By delivering this medication directly to the tumor instead of throughout the whole body, doctors hope to make the treatment more effective and easier to tolerate.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy on a repeating 4-week schedule. On day 1, you would receive one medication through an IV in your vein. On day 8, you would receive another IV treatment. On day 15, doctors would place a special catheter to deliver medication directly into the blood vessels feeding your tumor. Your progress would be checked every three weeks with blood tests and imaging scans to see how the cancer is responding.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~30 participants
Started
March 2024
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Yang, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.